Shenzhen - Delayed Quote • CNY SZSE Component Index Fund (ETF) (159903.SZ) Follow Add holdings 1.2090 -0.0100 (-0.82%) At close: 3:04:36 PM GMT+8 Related News Costco posts mixed earnings results as consumers seek value amid tariff uncertainty Costco posts earnings growth as the company navigates an uncertain macro landscape. Costco earnings top estimates despite tariffs Costco (COST) reported third quarter earnings of $4.28 per share compared to the Bloomberg consensus estimate of $4.24. Revenue was $63.21 billion versus an estimated $63.31 billion. Comparable sales, excluding gas and currency impacts, were up 8%. Analysts had anticipated 6.99%. Market Domination Overtime Anchors Julie Hyman and Josh Lipton are joined by Senior Reporter Brooke DiPalma to discuss the results. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. Uber, Tesla robotaxis, Synopsys guidance: Trending Tickers Uber (UBER) shares slide into negative territory on Thursday amid speculation around Tesla's (TSLA) rollout of robotaxis in Austin, Texas, on June 12. Catch Tesla investor Ross Gerber share his thoughts on Waymo's robotaxi model as compared to Tesla's plans. Synopsys (SNPS) suspends its guidance for its current fiscal third quarter and full-year 2025 as it digests new export controls on shipments to China. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. How bitcoin miners are powering the AI boom Some bitcoin (BTC-USD) miners are pivoting to artificial intelligence (AI) as the rapidly evolving tech's data center and power demands expand. BitFarms (BITF) CEO Ben Gagnon joins Catalysts with Madison Mills and Interactive Brokers chief strategist Steve Sosnick to dive into the phenomenon. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. The real winner in GameStop's bitcoin pivot is Strategy For a certain class of GameStop investor, chasing improbable upside is entirely the point. Sanofi, Regeneron shares nosedive after mixed Itepekimab results Investing.com -- Shares in Sanofi (EPA:SASY) (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) fell Friday after the pharmaceutical giants reported mixed results from two phase 3 trials of their investigational chronic obstructive pulmonary disease (COPD) treatment, Itepekimab. Where Will Costco Stock Be in 5 Years? Costco has built a near-unmatched empire in retail. Costco (NASDAQ: COST) has been one of the most dominant retailers in modern history. While Costco faces competition in the category from BJ's Wholesale and Walmart's Sam's Club, Costco is the clear leader in warehouse retail. Sanofi, Regeneron’s Itepekimab Delivers Mixed Results in Late-Stage Trials Sanofi and Regeneron said that drug candidate didn’t meet primary endpoint in a phase three study, although a benefit was seen earlier in the trial. UiPath Inc (PATH) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements UiPath Inc (PATH) reports a 12% increase in ARR and significant improvements in operating income, while navigating a variable macroeconomic environment. Marvell Technology Inc (MRVL) Q1 2026 Earnings Call Highlights: Record Revenue and Robust AI ... Marvell Technology Inc (MRVL) reports a 63% year-over-year revenue increase, driven by strong data center performance and strategic business moves. Dell Technologies Inc (DELL) Q1 2026 Earnings Call Highlights: Strong AI Server Demand and ... Dell Technologies Inc (DELL) reports robust growth in AI server orders and cash flow, despite a decline in consumer revenue and competitive pressures. Costco Wholesale Corp (COST) Q3 2025 Earnings Call Highlights: Strong Growth in Net Income and ... Costco Wholesale Corp (COST) reports a 13% increase in net income and significant e-commerce growth, while navigating challenges from tariffs and inflation. Ulta Beauty Inc (ULTA) Q1 2025 Earnings Call Highlights: Strong Sales Growth Amidst Margin Pressures Ulta Beauty Inc (ULTA) reports a 4.5% increase in net sales and expands its loyalty base, while navigating challenges in operating margins and market uncertainties. Zscaler Inc (ZS) Q3 2025 Earnings Call Highlights: Strong Growth Amid Economic Challenges Zscaler Inc (ZS) reports robust revenue and ARR growth, while navigating macroeconomic uncertainties and expanding its product portfolio. Analyst Views Split on Marvell (MRVL) – Here’s What They’re Watching We recently published a list of 10 AI Stocks on Wall Street’s Radar. In this article, we are going to take a look at where Marvell Technology, Inc. (NASDAQ:MRVL) stands against other AI stocks on Wall Street’s radar. On May 28, Stifel analyst Tore Svanberg reiterated a Buy rating on Marvell Technology, Inc. (NASDAQ:MRVL) with […] Ulta Beauty, Inc. (ULTA): A Bull Case Theory We came across a bullish thesis on Ulta Beauty, Inc. (ULTA) by @wallstengine on X (Twitter). In this article, we will summarize the bulls’ thesis on ULTA. Ulta Beauty, Inc. (ULTA)’s share was trading at $407.04 as of 23rd May. ULTA’s trailing and forward P/E were 16.06 and 17.89 respectively according to Yahoo Finance. Ulta Beauty (ULTA) […] Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit AERIFY-2, a second Phase 3 trial, did not meet the primary endpoint despite a benefit seen earlier in the trial Itepekimab was generally well tolerated in both AERIFY-1 and AERIFY-2, with safety consistent with prior clinical trials Regeneron and Sanofi are assessing the data and wi Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefitAERIFY-2 study, a second Phase 3 study, did not meet the primary endpoint despite a benefit seen earlier in the studyItepekimab was generally well tolerated in both AERIFY-1 and AERIFY-2Sanofi and Regeneron are as Nvidia and Dell to Supply Next US Department of Energy Supercomputer The U.S. Department of Energy stated that NVIDIA Corporation (NASDAQ:NVDA)’s future Vera Rubin chips and Dell Technologies Inc. (NYSE:DELL)’s liquid-cooled servers would power its next supercomputer. “Doudna” is scheduled to be deployed at Lawrence Berkeley National Laboratory in 2026. The technology, which bears the name of Nobel winner Jennifer Doudna, will assist 11,000 researchers in […] Watch These Boeing Price Levels After Stock Jumps to Highest Level in 15 Months Boeing shares surged Thursday after the company said it will resume delivering planes to China next month. Monitor these key support and resistance levels. Performance Overview Trailing total returns as of 5/30/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) Return 159903.SZ MSCI WORLD (^990100-USD-STRD) YTD -3.28% +4.23% 1-Year +8.53% +12.99% 3-Year -7.50% --